Volcano, a US-based developer of precision-guided therapy tools for the diagnosis of coronary and peripheral vascular diseases, has announced the US and European launch of its Valet microcatheter for use in highly stenosed lesions.
Valet microcatheter is available in sizes compatible with 0.014in (0.036cm) and 0.035in (0.089cm) guidewires and in lengths of 100cm, 135cm and 150cm.
The microcatheter, which Volcano claims to be the first product to use its proprietary VeriTorque technology, is used for guidewire support, wire exchange and contrast injections during complex coronary and peripheral interventional procedures.
When combined with Valet's shapeable distal tip, the technology provides a better torque performance, and helps physicians to precisely control and position the guidewire in distal and tortuous anatomy.
The device also provides a new level of guidewire crossing support on account of its powder-coated shaft and reinforced layers of microwire wind on the proximal segment of the catheter, according to the company.
St Luke's Mid America Heart Institute interventional cardiology research programme director Dr Barry Rutherford said Volcano has brought a new device for treating chronic coronary artery occlusions.
"I found the catheter to have excellent torque response and superb handling and tracking," Rutherford said.
"Valet offers compelling performance benefits in challenging peripheral endovascular cases."
Clear Lake Regional Medical Center cardiothoracic surgeon Dr Christos Katsigiannis said; "I particularly appreciated Valet's performance in navigating the complex anatomy below-the-knee."
Earlier in 2010, Volcano received CE mark approval for its vascular imaging balloon catheter, which can quickly access, prepare and evaluate lesions and allows physicians to see more detail right at the point of therapy.